A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection.

Trial Profile

A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir Plus Efavirenz Versus Lopinavir/Ritonavir Plus 2 NRTIs Versus Efavirenz Plus 2 NRTIs as Initial Therapy for HIV-1 Infection.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Efavirenz (Primary) ; Lamivudine; Lopinavir/ritonavir; Stavudine; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2017 Results of pooled analysis of 3 ACTG U.S based randomized trials (A5142, A5202 and A5257) presented at the 24th Conference on Retroviruses and Opportunistic Infections
    • 06 Apr 2012 Actual end date changed from May 2007 to Mar 2006 as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Results reporting European mitochondrial DNA halogroups and metabolic changes have been published in AIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top